Cost-effectiveness of Emollients in the Prevention of Relapse among French Patients with Atopic Dermatitis

被引：6

作者：

Cabout, Elise ^{[1
]}

Eymere, Sebastien ^{[1
]}

Launois, Robert ^{[1
]}

Seite, Sophie ^{[2
]}

Delvigne, Veronique ^{[2
]}

Taieb, Charles ^{[3
,4
]}

Reguiai, Ziad ^{[5
]}

机构：

[1] Reseau Evaluat Econ Sante REES, Paris, France

[2] La Roche Posay Dermatol Labs, Levallois Perret, France

[3] European Market Maintenance Assessment, EMMA, Fontenay Sous Bois, France

[4] Hop Necker Enfants Malad, Sante Publ, Paris, France

[5] Polyclin Courlancy Bezannes, Serv Dermatol, Reims, France

来源：

ACTA DERMATO-VENEREOLOGICA | 2021年 / 101卷

关键词：

dermatitis; atopic; secondary prevention; cost-benefit analysis; STRENGTHENING MOISTURIZING CREAM; UNCERTAINTY;

D O I：

10.2340/00015555-3873

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Atopic dermatitis affects up to 20% of children and quite frequently persists in adulthood. Follow-up, treat ment, and prevention of relapses have an impact on healthcare spending. The aim of this study was to assess the cost-effectiveness of different emollients prescribed for patients with atopic dermatitis in France. A 3-health state Markov model was designed, using French data for resource utilization, price and transition probabilities. The effects of the use of 5 different emollients (A, B, C, D, E) or no emollient were compared. The selected outcome was time (years) without flare-up. The 5-year cost for emollient A is 1,575.64euro, and the effectiveness is 3.89 years without flare-up. Strategy A is the most effective. Compared with treatment E, which was the least expensive emollient, A is more expensive (+481.84euro) and more effective (0.082 years without flare-up). The incremental cost-effectiveness ratio is 5,877.48euro/years without flare-up. In conclusion, treating atopic dermatitis with emollients is a cost-effective strategy.

引用

页数：7

共 37 条

[1] Comparison of Moisturizing Creams for the Prevention of Atopic Dermatitis Relapse: A Randomized Double-blind Controlled Multicentre Clinical Trial [J].